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Cellular senescence is a state of stable cell cycle arrest arising in response to DNA and mitochondrial
damages. Senescent cells undergo morphological, structural and functional changes that are influenced by a
number of variables, including time, stress, tissue, and cell type. The heterogeneity of the senescent
phenotype is exemplified by the many biological properties that senescent cells can cover. The advent of
innovative model organisms has demonstrated a functional role of senescent cells during embryogenesis,
tissue remodeling, tumorigenesis and aging. Importantly, prolonged and aberrant persistence of senescent
cells is often associated with tissue dysfunction and pathology, and is partially the consequence of
mechanisms that enhance survival and resistance to cell death. Here, we describe the main molecular players
involved in promoting survival of senescent cells, with particular emphasis on the regulation of senescence-
associated anti-apoptotic pathways. We discuss the consequences these pathways have in providing
resistance to intrinsic and extrinsic pro-apoptotic signals. Finally, we highlight the importance of these
pathways in the development of targets for senolytic interventions.
© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hallmarks of cellular senescence
Cellular senescence is a biological process char-
acterized by a stable proliferative arrest in response to
various stimuli (or SAGA, for senescence-associated
growth arrest). Unlike quiescent or terminally differ-
entiated cells, theSAGA is accompanied by analtered
secretome known as the senescence-associated
secretory phenotype (SASP) capable of influencing
the microenviroment [1]. Senescent cells also
undergo heterogeneous morphological, structural
and functional changes that depend on a number
of variables, including time, tissue, and cell type.
Although few common hallmarks of cellular senes-
cence exist (reviewed in Ref. [2]), the senescent
phenotype is highly diverse, with underlying mecha-thor(s). Published by Elsevier Ltd. This is
ses/by-nc-nd/4.0/).nisms not necessarily conserved among the various
senescence programs. This diversity is reflected by
the lack of specific markers and by the necessity to
measure multiple facultative senescence-associated
markers for the identification of senescent cells both in
cell culture and in vivo. These markers include the
following: (i) high level of p16INK4a and/or p21CIP1,
which prevent cell cycle progression by inhibiting the
cyclin-dependent kinases CDK4 and CDK6 [3]; (ii)
enhanced activity of the lysosomal senescence-
associated β-galactosidase (SA-β-gal) [4]; (iii) persis-
tent DNA-damage checkpoint response (DDR) as
shown by the presence of p53-binding protein 1
(53BP1) and/or γH2AX foci [5] and (iv) formation of
specialized domains of facultative heterochromatin
which contribute to the silencing of proliferation-
promoting genes (called the senescence-associated
heterochromatin foci, SAHF) [6]. Additional predictive
markers include a flattened morphology, absence of
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Fig. 1. Cellular fates of damaged cells. Following DNA damage, normal cells engage a temporary growth arrest and
attempt to repair their DNA. If unresolved, damaged cells may initiate apoptosis or other forms of regulated cell death and
be removed via efferocytosis. Alternatively, damaged cells may become senescent and persist indefinitely within tissues
until their removal by the immune system. However, if damage becomes exacerbated, senescent cells may be susceptible
to necrotic cell death, further promoting inflammation. Senolytic drugs aim to initiate pro-apoptotic pathways in senescent
cells without affecting normal cells.
2630 Survival networks in senescent cellsproliferation markers such as Ki67, lack of EdU/BrdU
incorporation, enlarged nuclear size, loss of nuclear
high mobility group box 1 (HMGB1) and decreased
expression of lamin B1 [7–9]. Cellular senescencewas
initially described in response to excessive telomere
shortening from continued proliferation, and this form is
now referred to as replicative senescenceorRS [10]. In
contrast, premature senescence is triggered by a
variety of inducers not associated with short atrophied
telomeres. Therapy-induced senescence and oxida-
tive stress-induced senescence arise in response to
genotoxic insults. Spontaneous activation of various
oncogenes can result in oncogene-induced senes-
cence [11], a form characterized by proliferative bursts
and DNA-hyper replication that engage a sustained
DDR signaling [12]. Paracrine senescence can origi-
nate when normal cells are continuously exposed tosenescent cells and the SASP [13]. Lastly, in recent
years, a number of programmed senescent states
associated with tissue remodeling have been identified
both during embryogenesis (developmental senes-
cence [14,15]) and adulthood (tissue repair senes-
cence [16]).
The choice of cellular senescence
Genetic injuries can arise from endogenous
(metabolic byproducts of cellular respiration, col-
lapsed replication forks, progressive telomere short-
ening, etc.) and exogenous sources (UV light,
ionizing radiation, harmful environmental agents, or
cytotoxic drugs). To face these lesions, the DDR
transiently blocks cell cycle progression via p21CIP1,
while DNA repair is attempted. If the damage is
2631Survival networks in senescent cellsresolved, the cell can re-enter the cell cycle;
however, not all DNA damage can be readily
repaired, and when faced with irreparable damage,
normal cells can become senescent, converting their
temporary growth arrest into an indefinite one (the
SAGA). Alternatively, damaged cells may not be-
come senescent and instead initiate apoptosis or
other forms of regulated cell death. Determinants of
the molecular cell fate are still under investigation,
but the extent of cellular damage has a major
influence in the choice between cellular senescence
and apoptosis. For instance, treatment with DNA-
damaging agents induces cellular senescence at
low doses and apoptosis at high doses, as demon-
strated after treatment with cisplatin [17,18], etopo-
side [19], doxorubicin [18,20], temozolomide [18],
placlitaxel [18], H2O2 [21], UV-B [22,23], and ionizing
radiation (reviewed in Ref. [24]). Senescence is
similarly observed after treatment with sub-lethal
doses of proteotoxic drugs such as thapsigargin or
dithiothreitol [25,26]. Remarkably, although trans-
formed cancer cells have partially lost the capacity to
signal senescence or apoptosis, various forms of
chemotherapy or radiation can inflict severe DNA
damage and re-activate these signaling pathways
resulting in therapy-induced senescence or apopto-
tic cell death [27,28]. Indeed, conventional anticancer
treatments exploit these outcomes leading to tumor
regression and increased tumor-specific immune
activity (reviewed in Ref. [29]). However, therapy-
induced senescent cells can persist after treatment
and contribute to the adverse effects of chemotherapy
and to cancer relapse via the SASP [18].
Physiologically, the choice between cellular senes-
cence and apoptosis differs greatly from an immuno-
genic perspective. Apoptosis is generally recognized
as an anti-inflammatory cell-death (reviewed in Ref.
[30]) and is normally followed by the rapid engulfment
of apoptotic cell by phagocytes in a process called
efferocytosis. Efferocytosis prevents the release of
the inner contents of apoptotic cells that would
otherwise act as damage-associated-molecular pat-
terns and perpetuate an inflammatory response.
Likewise, efferocytosis is followed by the release of
anti-inflammatory cytokines such as TGF-β and IL-10
[30]. On the other hand, senescent cells are regarded
as pro-inflammatory and immunogenic, playing active
roles in the recruitment and activation of the immune
system (reviewed in Ref. [31]). Furthermore, senes-
cent cells may persist indefinitely within tissues until
their removal by the immune system, or after necrotic
cell death and other forms of cell death from
exacerbated damage (Fig. 1).
Recent evidence suggests that an incomplete or
stalled apoptotic phenotype termed “senoptosis”
may also occur in human fibroblasts after being
subjected to low-dose ionizing radiation [32]. Senop-
totic cells are a viable and stable sub-G1 population
that has undergone controlled cleavage of nuclearDNA, reminiscent of the chromatin degradation
process normally observed in apoptotic cells. Similar
to senescent cells, senoptotic cells were unable to
proliferate, remained stably viable, and tested
positive for SA-β-gal; however, unlike senescent
cells, senoptotic cells lacked canonical pro-
inflammatory components of the SASP, suggesting
that senoptotic cells may not undergo an immuno-
genic conversion. Importantly, the immunogenic
phenotype of senescent cells lies behind its various
functions under physiological conditions by facilitat-
ing immune infiltration, and activating innate and
adaptive immune responses (reviewed in Ref. [31]).
Function of senescent cells
The heterogeneity of the senescent phenotype is
exemplified by the intrinsic differences that distin-
guish each senescent program [33] and by the
complex biological roles that senescent cells can
cover, appearing at times even paradoxical: acting
both as tumor suppressor or tumor promoter, limiting
or exacerbating fibrosis, and enhancing tissue repair
and regeneration while equally contributing to age-
related pathologies via tissue degeneration [34].
Indeed, the phenotype and the impact of senescent
cells at the tissue and organismal level greatly
depend on the physiological context. Cellular se-
nescence acts beneficially as a barrier to tumori-
genesis by limiting the growth of damaged
potentially oncogenic cells in a cell-autonomous
manner via the SAGA. Meanwhile, components of
the SASP such as IL-6 and IL-8 act in autocrine
fashion to reinforce growth arrest through a positive
feedback loop [13]. Furthermore, the release of
SASP growth factors favors tissue repair by promot-
ing the division of new healthy cells, paired with
secreted matrix metalloproteinases that enable
efficient tissue remodeling and limit fibrosis [1,16].
Importantly however, secretory components may
exert beneficial functions in the short term but
promote deleterious effects on the surrounding
microenvironment if unresolved. For instance, the
accumulation of secretory components meant to
reinforce cell-cycle arrest may act in a paracrine
manner potentially propagating the senescent phe-
notype to neighboring cells and hampering the
regenerative capacity of the surrounding tissue.
Similarly, persistent pro-inflammatory signaling
meant to promote immune cell infiltration may
eventually result in disruptive chronic inflammation
and impaired tissue homeostasis via paracrine
senescence. The advent of innovative model organ-
isms has demonstrated that prolonged persistence
of senescent cells is associated with tissue dysfunc-
tion and pathology. Indeed, senescent cells have
been implicated in several age related pathologies
such as sarcopenia (loss of skeletal muscle mass)
[35], lordokyphosis (increased curvature of the
2632 Survival networks in senescent cellsspine) [35], cataracts [35], hair loss [36], osteoporo-
sis [37], aged hematopoietic system [38], vasomotor
dysfunction [39], neurodegeneration [40], pulmonary
fibrosis [41], and decreased lifespan [42,43]. Ac-
cordingly, genetic or pharmacologic clearance of
senescent cells is sufficient in delaying these age-
related phenotypes and helps restore a pro-
regenerative environment [35–44]. The beneficial
effects related to senescent cell clearance have
sparked great interest in the development of a novel
pharmacological strategy, termed senolytics, which
aims to selectively eliminate senescent cells by
effectively overcoming the survival mechanisms of
senescent cells while sparing normal quiescent and
proliferating cells.Activation of Survival Mechanisms
Senescent cells seem to be more resistant to
apoptosis compared to normal proliferating cells. An
increased apoptosis resistance is reported in re-
sponse to several stimuli, including serum withdraw-
al [45], UV damage [23,36,46], oxidative stress
[47,48], extrinsic apoptosis inducers [36,49], and
treatment with cytotoxic drugs such as staurosporine
or thapsigargin [23,50]. Given the underlying stress
present in senescent cells prior to exposure to
apoptotic stimuli, an increased susceptibility to cell
death would perhaps be expected, and may well be
the case in some cell types, such as endothelial
cells [51]. However, the observations of increased
survival, at least in senescent fibroblasts and
keratinocytes, attest to the role of cellular senes-
cence as an adaptive response. In recent years, a
number of studies have shown that the enhanced
survival of senescent cells depends on the activation
of various mechanisms referred to as senescent cell
anti-apoptotic pathways (SCAPs). SCAPS are di-
rectly related to many features of the senescent
phenotype such as the SAGA, the SASP, the
unfolded protein response (UPR), and the PI3K-Akt
signaling. Importantly, SCAPs are now under inves-
tigation as targets for senolytic drugs.
The SAGA
Since proliferation is an essential feature for the
effectiveness of many DNA-damaging agents [52],
the SAGA may provide a survival advantage to
senescent cells. p21Cip1 is an early effector of cell
cycle arrest following DNA damage and p53
signaling. However, p21Cip1 is also induced in p53-
and DNA damage-independent situations such as
tissue development, serum stimulation, and cellular
differentiation [53]. Recently, p21Cip1 was revealed
to play a role in maintaining senescent cell viability
under persistent DDR signaling [54]. Knockdown of
p21Cip1 in DNA damaged-induced senescent cells,but not oncogene-induced senescence cells, result-
ed in the accumulation of DNA lesions that activated
ATM and NF-κB, TNF-α secretion, JNK signaling,
and increased cell death. Importantly, these effects
were not limited to normal fibroblasts but were also
observed in a p53 mutated non-small cell lung
cancer cell line (H1299) [54]. Importantly, cell death
was only partially rescued with the pan-caspase
inhibitor Q-VD-OPh, but fully rescued in combination
with JNK inhibition. Importantly, JNK activation can
shift the balance of TNF-stimulated cell death from
apoptosis to necrosis by increasing the production of
cytotoxic reactive oxygen species (ROS) [55]. These
findings suggest alternative modes of cell death
additional to apoptosis may also be involved. p21-
Cip1 may therefore prevent the exacerbation of DNA
damage from the continued proliferation of DNA-
damaged cells, eventually tipping cell fate balance
from cellular senescence into apoptosis or necrosis
[54]. However, two important notions challenge that
the pro-survival effects of p21Cip1 are exclusively
related to cell cycle progression. First, knockdown of
the other main senescence-associated CDKi, p16-
INK4a, is normally not lethal for senescent cells [56].
Second, p21-proficient, p53-null cancer and near-
normal cell models showed that after an initial
senescence-like phase, a subpopulation of p21-
expressing proliferating cells emerged, featuring
increased replication stress, genomic instability,
aggressiveness, and chemoresistance [57].
The SASP
In contrast to quiescent cells, the SAGA is
accompanied by a secretory phenotype (the SASP)
composed of major inflammatory factors. SASP IL-6,
IL-8, IL-1, and TNFα help reinforce growth arrest via
autocrine NF-κB signaling and ROS generation.
However, activation of NF-κB may also promote
survival responses by transcriptional induction of
anti-apoptotic proteins of the Bcl-2 family [58–61]
often overexpressed in senescent cells [36,45,62].
The SASP also includes several growth factors
like IGF-1, PDGF, and VEGF proposed to act in a
paracrine manner to fuel the proliferation of nearby
healthy cells, thereby promoting tissue repair and
regeneration [16]. In tumor contexts, these growth
factors may be taken up by surrounding cancer cells
and be responsible for some of the pro-tumorigenic
effects of senescent cells [63]. However, growth
factors may also promote survival in established
senescent cells. IGF-1 binds to the tyrosine kinase
receptor (TKR) IGF1R and leads to the upregulation
of the PI3K/AKT pathway, leading to cell growth and
proliferation during acute signaling but inducing
premature senescence after prolonged signaling in
a p53-dependent manner [64]. In normal cells, p53
negatively regulates basal-levels of IGF-1 but
upregulates IGF-1 in response to chemotherapy,
2633Survival networks in senescent cellsionizing radiation, and genomic instability providing a
survival advantage in a p53-ATM-DDR dependent
manner [65]. Accordingly, IGF-1 inhibition delays
senescence in proliferating cells, while inducing
apoptosis in senescent fibroblasts [65].
Additional SASP components and their TKRs may
act in parallel or play autonomous roles in a cell type-
dependent manner. For instance, multiple TKRs act
as dependence receptors: specialized surface re-
ceptors that activate classic signaling pathways
implicated in cell survival in the presence of their
cognate ligand, while eliciting caspase-dependent
apoptotic signals in the absence of a ligand
(reviewed in Ref. [66]). Senolytic screens have
identified the upregulation of ephrin dependence
signaling in senescent cells via the ephrin ligands
(EFN) B1, and EFNB3 [62]. Targeting EFN signaling
with the antioxidant and promiscuous drug quercetin
increased cell death of human senescent preadipo-
cytes, but was much less effective on senescent
endothelial cells. Only the combination of quercetin
and dasatinib (a PI3K and serpine inhibitor) resulted
in cell death of both senescent cell types, highlight-
ing the reliance of senescent cells on multiple pro-
survival pathways.
Importantly, mTOR signaling is a major regulator
of the SASP by promoting translation of IL-1A [67]
and of the mitogen-activated protein kinase activat-
ed kinase 2 (MAPKAPK2), responsive to multiple
stress stimuli (e.g., cytokines, ultraviolet and ionizing
irradiation, ROS) [68,69]. Recently, a senescence-
associated secretory switch mediated by mTOR and
PI3K/Akt signaling has been described in endothelial
cells, exerting various chemoprotective effects [70].
Inhibition of mTOR with the drug rapamycin strongly
represses the SASP of senescent cells [69], while
preventing senescence-associated morphological
changes and delaying senescence in treated cells
[67]. Put together, these findings highlight the
importance of mTOR in incorporating inputs from
multiple stresses, as well as the role of the SASP in
establishing the senescent phenotype.
The UPR
The SASP exerts proteotoxic stress through the
accumulation of unfolded proteins in the endoplas-
mic reticulum (ER) and triggers an UPR. The UPR is
an adaptive mechanism intended to restore protein
homeostasis by activating a cascade of transcription
factors that regulate genes encoding chaperones,
and components of the ER-associated protein
degradation system and of the autophagy machinery
(reviewed in [71]). Importantly, the UPR is a key
player in the regulation of multiple morphological
aspects of the senescent phenotype such as
cytoskeleton-mediated shape changes, size en-
largement, and organelle remodeling [25]. Treat-
ment of normal fibroblasts with sub-lethal doses ofthe drug thapsigargin, an ER stress inducer,
culminates in premature senescence [25]. Interest-
ingly, if ER stress precedes additional DNA damage,
p21Cip1 is suppressed, and the apoptotic threshold
to genotoxic treatments is lowered [72]. However,
senescent fibroblasts showed an increased resis-
tance to ER stress compared to young non-
senescent fibroblasts [73], presumably due to pre-
established UPR signaling serving as a coping
mechanism.
Oxidative stress is a common feature of senescent
cells, which can act either as inducer or sustainer of
the senescent phenotype (reviewed in Ref. [74]).
However, ROS inflict damage to various cellular
components including proteins, lipids, and nucleic
acids and contributes to ER stress and UPR
signaling. When ER stress is unresolved, cells
heavily rely on autophagy to avoid cell death [75].
How ER stress activates autophagy remains un-
clear, but the UPR may play an active role by
enabling the transcription of autophagy components
[71]. Autophagy allows the degradation of cytosolic
proteins and contributes to the clearance of all
irreversibly oxidized biomolecules, thereby prevent-
ing oxidative stress from culminating in cell death
[76]. Indeed, lack of autophagy leads to lysosomal
and mitochondrial impairment in senescence and
oxidative stress-induced senescence [77], while
increased autophagy is a feature of senescent
fibroblasts and endothelial cells [71,78,79]. In
contrast, high levels of dysregulated autophagy
may result in the degradation of important cellular
structures leading to autophagy-dependent cell
death and not apoptosis, as described for senescent
keratinocytes [80,81]. These findings suggest that
senescent cells may depend on tightly regulated
levels of autophagy: on one hand, enhanced
autophagy attenuates existing proteotoxic stress
and promotes cell survival [82]; on the other hand,
limiting autophagy is a necessary step to prevent
autophagy-dependent cell death. A balanced level of
autophagy in senescent cells may be regulated via
Bcl-2 and homolog proteins. Although anti-apoptotic
Bcl-2 proteins are primarily known for their inhibitory
role in the intrinsic pathway of apoptosis, Bcl-2 can
directly interact with the evolutionarily conserved
autophagy protein Beclin1 and inhibit autophago-
some formation [83]. As some senescent cells
overexpress Bcl-2, Bcl-2 may serve an anti-
autophagic function and protect from autophagy-
dependent cell death, in addition to its anti-apoptotic
roles.
Importantly, mTOR is a master regulator of
autophagy. When nutrients like glucose and ami-
noacids are freely available, mTOR is found in
complexes where it blocks autophagy and promotes
protein synthesis (reviewed in Ref. [84]). Specifical-
ly, mTOR complex 1 (mTORC1) inactivates autoph-
agy by inhibiting unc-51 like autophagy activating
Fig. 2. Crosstalk between SAGA, secretory phenotype and UPR. Senescent cells are insensitive to extracellular
mitogenic stimuli signaling from TKRs due to the overexpression of cyclin dependent kinase inhibitors (e.g., p21, p16)
resulting in a senescent-associated growth arrest (the SAGA). Growth arrest is reinforced by the secretory phenotype of
senescent cells (the SASP) through the amplification of autocrine loops. An overactive SASP results in ROS generation
and proteotoxic stress, which engage the UPR responsible for many adaptive morphological changes associated with
senescent cells. However, unresolved proteotoxic stress results in autophagy, which helps attenuates proteotoxic stress
and limit cell death. In turn, autotophagy is limited by mTORC1 signaling and Bcl-2, which may serve protective effects
against autophagic cell death in senescent cells.
2634 Survival networks in senescent cellskinase 1/2 (ULK1/2) and promoting protein synthesis
via S6 kinase (S6K). In contrast, when nutrients are
low, mTOR complexes are inactivated and the cell
can engage in autophagy, allowing the degradation
and recycling of cytosolic proteins to satisfy a
shortage of aminoacids. mTORC1 therefore plays
an important role in promoting the SASP while
limiting autophagy and potentially autophagic-
programmed cell death (Fig. 2).
Metabolic reprogramming
In addition to autophagy, senescent cells display
other metabolic changes such as increased glycol-
ysis and increased mitochondrial metabolism
[82,85]. Metabolic reprogramming may serve as a
cellular adaptation to an overactive secretory phe-
notype resulting in increased nutrient requirements
in the form of energy and amino acids. Indeed, SASP
production has been shown to rely on increased
glycolysis and enhanced ATP production in mito-
chondria [82], while a shortage of amino acids may
be overcome by coupling autophagy to protein
synthesis [86]. In addition to restore protein homeo-stasis, the UPR controls other pathways of lipid and
energy metabolisms, suggesting metabolic repro-
gramming [71]. Importantly, the increased energetic
demands and metabolic reprogramming of the
senescent response can sensitize senescent cells
to blockade of glucose usage [82], inhibition of
autophagy [82], and mitochondrial targeting [87].
Metabolic pathways might thus represent a thera-
peutically exploitable target.
Mitochondrial metabolism in cellular senescence
remains controversial. If senescent cells would
depend on increased mitochondrial activity to meet
energy requirements, mitochondrial depletion would
perhaps result in cell death. Instead, mitochondrial
depletion resulting in senescence bypass and ATP
production is compensated by increased glycolysis
[88]. Indeed, mitochondria appear to be required for
the establishment of the senescent phenotype
through a DDR-dependent feedback loop involving
ROS-ATM-Akt-mTORC1 and leading to PGC-1β-
dependent mitochondrial biogenesis [88]. Inhibition
of mTORC1 via rapamycin or PGC-1β deletion prior
to DDR activation reduced the expression of various
mitochondrial proteins pertaining to oxidative
Fig. 3. Metabolic reprograming of senescent cells. IGF-1R signaling activates PI3K leading to membrane PIP3
enrichment serving as an anchor for 3-phosphatidylinositol-dependent kinase 1 (PDK1) and Akt activation at position
T308. Among its multiple functions, Akt indirectly enables the formation of mTORC1. mTORC1 positively regulates protein
translation through S6K, which exerts negative feedback inhibition at the level of IGF-1R. PI3K also activates mTORC2,
which further activates Akt, increasing its kinase activity. Fully activated Akt can then efficiently inhibit pro-apoptotic Bad.
Akt may also inhibit pro-apoptotic FoxO transcription factors FoxO1/3, thereby preventing apoptosis. In contrast, anti-
apoptotic FoxO4 present in senescent cells also supports senescent cell viability [93].
2635Survival networks in senescent cellsphosphorylation complexes. Accordingly, increased
respiration and oxidative stress are crucial mediators
of oncogene-induced senescence, and rely on the
mitochondrial gatekeeper pyruvate dehydrogenase
for enabling the use of pyruvate in the tricarboxylic
acid cycle [85]. Intriguingly, in the absence of DNA
damage, mitochondrial impairment leads to modified
form of senescence with a p53-mediated SAGA and
a modified SASP lacking the IL-1-dependent inflam-
matory arm, presumably due to p53 inhibition of NF-
κB [89]. This form of senescence was termed
mitochondrial dysfunction-associated senescence
(MiDAS) and appears to be independent of ROS.
Antioxidant treatment inhibiting mitochondrial ROS
failed to prevent MiDAS, whereas treatment with
pyruvate prevented MiDAS growth arrest but re-
stored NF-κB activity, supporting the notion that the
SAGA and the SASPmay be uncoupled. Resistance
to apoptosis was not explored in MiDAS cells, and
the levels of mitochondrial pro-apoptotic and anti-
apoptotic components were not characterized. AsNF-κB activity signaling was absent in MiDAS cells,
it is tempting to speculate that Bcl-2 homologs may
be reduced compared to “conventional” senescent
cells.
It is unclear whether increased energy require-
ments are truly a limitation in senescent cells, as
nutrients can be made freely available in cell
cultures, well-fed animal models, and aging humans,
without necessarily delaying senescence. In fact, the
opposite may be true as caloric restriction delays
senescence [90] and is widely recognized as a
lifespan extension intervention [91]. Nutrient avail-
ability may therefore play a role in the survival
senescent cells. For instance, high glucose uptake
leads to insulin release, a hormone structurally
similar to IGF-1. Although both hormones have
different affinities to the IGF-1 receptor, both are
capable of binding and initiating downstream signal-
ing. Activated IGF-1R recruits phosphatidylinositol-3
kinase (PI3K) to the cell membrane, which then
phosphorylates phosphatidylinositol-biphosphate
Table 1. Apoptotic ligands, receptors and decoy receptors






2636 Survival networks in senescent cells(PIP2) into phosphatidylinositol-triphosphate (PIP3).
The enrichment of PIP3 phospholipids at the cell
membrane serves as an anchor fo r 3 -
phosphatidylinositol-dependent kinase 1 (PDK1),
which next activates the pro-survival kinase Akt at
position T308. Among its multiple functions, Akt
indirectly enables the formation of mTORC1. In turn,
mTORC1 positively regulates protein translation
through S6K, which exerts negative feedback
inhibition at the level of IGF-1R. However, in contrast
to mTORC1, mTORC2 has a direct role in cell
survival, and IGF-1R signaling can also activate
mTORC2 in a PI3K-dependent manner. Once
activated, mTORC2 further phosphorylates Akt in
position S473, increasing its kinase activity over 10-
fold. Activated Akt can then efficiently inhibit the pro-
apoptotic protein Bad, which initiates Bax-Bak
dependent mithochondrial pathway of apoptosis
[92]. Alternatively, Akt can also inhibit forkhead box
O (FoxO) transcription factors FoxO1/3, thereby
preventing apoptosis (reviewed in Ref. [84]). More-
over, anti-apoptotic FoxO proteins such as FoxO4
may be present in senescent cells [93]. FoxO4
inhibition prior to senescence induction resulted in
Bax/Bak-dependent release of mitochondrial cyto-
chrome C and apoptosis, suggesting that FoxO4
favors senescence over apoptosis. Accordingly,
inhibiting the interaction of FoxO4 and p53 with a
therapeutic peptide resulted in decreased viability of
already senescent cells, and amelioration of age
related phenotypes [93] (Fig. 3).Apoptotic Signaling in Senescent Cells
Intrinsic apoptosis pathway
Although senescent cells are proposed to be
resistant to apoptosis, an upregulation of pro-
apoptotic “initiators” such as PUMA and BIM has
been described, surprisingly coupled to a reduction
of anti-apoptotic Bcl-2 [93]. These findings suggest
that senescent fibroblasts may be primed to
undergo apoptosis, but that the execution of the
death program might be restrained. During the
mitochondria-mediated intrinsic pathway of apopto-
sis, pro-apoptotic initiators (e.g., tBid, BIM, PUMA,
etc.) activate Bax and Bak, which permeabilize the
mithochondria and allow the release of cytochromeC. Cytochrome C and the apoptosis protease factor-
1 (Apaf-1) assemble the apoptosome, an important
structure capable of activating caspase signaling
resulting in the rapid cleavage of multiple substrates
within the cell (e.g., caspase-9, caspase-3, etc.). In
contrast, anti-apoptotic Bcl-2 homolog proteins such
as Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 are primarily
known for their inhibitory role in the intrinsic pathway
of apoptosis by sequestering Bax and Bak and
thereby preventing the leakage of cytochrome C and
apoptosome formation (reviewed in Ref. [94]).
Although the levels of pro-apoptotic factors in
senescent cells are for the most part unclear, several
articles report dependence of senescent cells on
anti-apoptotic Bcl-2 homolog proteins [36,45,62].
Accordingly, targeting anti-apoptotic Bcl-2 homolog
proteins using pharmacological inhibitors ABT-263,
ABT-737, A1331852, and A1155463 resulted in
apoptosis of various senescent cell types without
affecting the viability of normal cells, confirming their
potential uses as senolytic drugs [36,38,95,96].
However, these findings also highlighted that Bcl-2
homolog proteins may act in a redundant manner to
protect senescent cells from apoptotic death [38],
limiting the potential of senolytic drugs based on
interfering with this pathway.
Extrinsic apoptosis pathway
Extrinsic apoptosis is a type of programmed cell
death initiated extracellularly through the engage-
ment of death receptor signaling on the target cell
(reviewed in Ref. [97]). Death receptors are trans-
membrane proteins of the tumor necrosis factor
(TNF) receptor superfamily that contain a cytoplas-
mic “death” domain capable of transducing an
extracellular apoptotic signal into intracellular sig-
naling pathways. The most studied death receptors
are TNF receptor 1 (TNFR1), CD95 (Fas), and TNF-
related apoptosis inducing ligand-receptor (TRAIL)
receptors 1 and 2 (TRAIL-R1 and TRAIL-R2, also
known as DR4, and DR5; Table 1).
Upon ligand binding, death receptors can trimerize
and recruit specialized adaptor proteins via their
death domain such as Fas-associated death domain
(FADD). In turn, FADD can recruit pro-caspase 8
and form a death-inducing signaling complex (DISC)
capable of generating mature caspase-8 through
self-cleavage. Mature caspase-8 can next activate
downstream effector caspases such as caspase-3,
as well as reinforce apoptosis by engaging the
intrinsic apoptosis pathway through proteolytic
cleavage of the pro-apoptotic protein Bid into t-Bid.
Caspase-8 therefore plays an essential role in
apoptosis induction by connecting the extrinsic
pathway of apoptosis with the intrinsic mitochondrial
pathway. Although it was reported that senescent
fibroblasts might increase their resistance to apo-
ptosis via reducing capsase-3 activity [23], the
Fig. 4. Intrinsic and extrinsic pathways of apoptosis in senescent cells. The extrinsic pathway of apoptosis is initiated
upon binding of apoptotic ligands (TRAIL, FasL) to their respective death receptors (DR4/5, Fas). Activated death
receptors recruit adaptor protein FADD, which binds to pro-caspase 8 to form a DISC capable of generating mature
caspase-8 through self-cleavage. Caspase-8 can next activate downstream effector caspases such as caspase-3 and
reinforce apoptotic signaling by engaging the intrinsic apoptosis pathway through proteolytic cleavage of Bid into t-Bid. tBid
and other proapototic proteins such as Bim activate Bax and Bak, which permeabilize the mithochondria and allow the
release of cytochrome C. Cytochrome C together with Apaf-1 assembles the apoptosome, which activates caspase-9 and
effector caspase-3 resulting in the rapid cleavage of multiple substrates within the cell. In contrast, anti-apoptotic Bcl-2
homolog proteins sequester Bax and Bak, thereby preventing cytochrome C leakage. Pro-apoptotic Bad can bind to anti-
apoptotic Bcl-2 proteins, indirectly promoting apoptosis. However, PI3K-Akt signaling may inhibit pro-apoptotic
components such Bad or caspase-9.
2637Survival networks in senescent cellsdevelopment of genetic mouse models of inducible
death of senescent cells suggest differently. Genetic
mouse models of senescent cell clearance include
p16-3MR mice (p16 inducible three modality reporter
[16]) and INK-ATTAC mice (apoptosis through tar-
geted activation of caspases [35]). Although mecha-
nistically different, treatment with an exogenous drug
in both models result in caspase 8 activation and
downstream signaling, suggesting that senescent
cells are readily capable of caspase-mediated apo-
ptosis, at least downstream of caspase 8 (Fig. 4).
Upstream of caspase-8, cFLIP is a negative
regulator of extrinsic apoptosis, and it competes
with procaspase-8 for binding to FADD and thus
prevents DISC formation. cFLIP is partially respon-
sible for TRAIL resistance in normal cells [98] but is
downregulated in response to DNA-damage [99], as
well as with the activation of the Myc oncogene inpre-transformed and fully transformed fibroblasts
[100]. Moreover, cFLIP expression was shown to
decreasewith progression into senescence in primary
(thymic) epithelial cells, where its expression is
regulated via NF-κB activation [101]. These findings
suggest that cFLIP may not play a role in senescent
cell resistance, while supporting the notion senescent
cells may be instead primed to apoptosis.
At the cytoplasmic membrane level, decoy receptors
(DcRs) may play a role in resistance to extrinsic
apoptosis. DcRs are extracellularly similar to death
receptors but lack an intracellular death domain.
Consequently, DcRs compete for ligand binding but
are incapable of signal transduction, serving as
inhibitory mechanisms of extrinsic apoptosis. The
upregulation of DcR1 [1,8,102] (TNFRSF10C) and
DcR2 [49,103–106] (TNFRSF10D) hasbeenproposed
as marker of senescence. Interestingly, the SASP also
2638 Survival networks in senescent cellsincludes soluble DcRs such as osteoprotegerin, which
binds both to TRAIL and to Receptor activator of
nuclear factor kappa-Β ligand (RANKL) [1,107].
So far, a protective role has only been demon-
strated for DcR2 in human senescent fibroblasts,
where silencing of DcR2 using siRNA or shRNA
increased susceptibility to TRAIL-induced extrinsic
apoptosis [49]. However, non-transformed (normal)
cells are already resistant to TRAIL-induced apopto-
sis due to multiple redundant pathways [98]. An
increased resistance of senescent cells in a previ-
ously sensitive population, such as cells that have
undergone malignant transformation and that were
induced into senescence by genotoxic stress,
remains to be described. Evidence suggests that
chemotherapy and ionizing radiation may instead
sensitize cancer cells to extrinsic apoptosis via the
upregulation of DR5 and the downregulation of c-
FLIP, thereby promoting DISC formation and over-
coming DcR2 upregulation [99,108].
Despite an increased resistance of senescent
fibroblasts to treatment with all extrinsic apoptosis
inducing ligands (Fas [49], TRAIL [49], and TNF-alpha
[36]), an increased resistanceacross cell types seems
unlikely. For instance, replicative senescent endothe-
lial cells aremore sensitive than early passage cells to
both FasL [109] and TNF-alpha [110]. Furthermore,
recent evidence suggests that human embryonic
stem cells, as well as induced pluripotent stem cells,
express all the canonical components of the extrinsic
apoptotic signaling pathway, irrespective of their origin
[111]. These cells were found to be initially resistant to
TRAIL, but sensitization was induced upon stress
derived from proteosynthesis inhibition. Accordingly,
an increased susceptibility to extrinsic cell death via
TRAIL was observed in human embryonic stem cells
following treatment with the chemotherapeutic drug
cisplatin, a known inducer of senescence [112].
However, cisplatin-treated human embryonic stem
cells were not characterized as senescent and
treatment with TRAIL was performed only 24 h after
treatment with cisplatin, suggesting that a senescent
response had not yet been fully established and
matured. Nevertheless, these results are similar to the
synergistic effects of TRAIL-mediated targeting of
DR5 in combination with cisplatin [113] or with ER
stress inducers [114], as reported in tumor context.
Together, these findings suggest that an increased
resistance to extrinsic apoptosis is not a conserved
feature of senescent cells.Immunogenicity of senescent cells
Immune-mediated clearance
The role of the innate immune system in immune-
mediated clearance of senescent cells via phago-cytes, such as macrophages, has been described for
developmental senescence, tissue-repair senes-
cence, and oncogene induced senescence. Howev-
er, most forms of cellular senescence are proposed
to be cleared through the degranulation of natural
killer (NK) cells [49]. NKG2D stress ligands are
reportedly upregulated in replicative, oncogene-
induced, and therapy-induced premature senes-
cence, where they interact with the NKG2D receptor
on NK cells and trigger the release of perforin-filled
granules [115]. Upon degranulation, perforin-formed
pores enable granzyme penetration and caspase
activation to induce apoptosis of the target cell.
Accordingly, perforin knockout mice accumulate
more senescent cells in their tissues with age and
display chronic inflammation and increased tissue
fibrosis [116]. Similarly, a dependence on the NKG2D
receptor–ligand interaction has been recently ob-
served in the removal of senescent cells by uterineNK
cells in cycling human endometrium [117].
The role of the adaptive immune system is less
understood but is proposed to likewise contribute to
senescent cell surveillance, at least in tumorigenic
contexts such as oncogene induced senescence. In
this case, the mounting of an adaptive response
against senescent cells is proposed to occur via
(CD4) T cells and to be dependent on the upregu-
lation of MHC class II molecules on the surface of
senescent cells [118,119]. The search for additional
senescence-associated cell-surface antigens is still
ongoing, but a recent study identified a majority of
poly-reactive antibodies capable of discriminating
senescent cells [120]. Said antibodies were of the
IgM isotype of the innate immune system and bound
to a surface exposed oxidative adduct of the
intermediate filament vimentin. These findings sug-
gest oxidized products resulting from increased ROS
in senescent cells may result in the generation of
neoantigens recognizable by the immune system as
additional “eat-me” signals. Markedly, the complex
dynamics of “eat-me” and “don't eat me” signals on
the surface of senescent cells remain to be fully
elucidated.
Immune checkpoints
The display of “eat-me” signals such as phospha-
tidylserine is required but not sufficient for the
immune clearance of apoptotic cells. Instead, “eat-
me” signals need to be paired to the downregulation
of “don't eat me” and immunosuppressive signals
normally expressed in healthy cells, such as CD47
(reviewed in Ref. [121]). A recent study suggests that
healthy cells display CD47 in high-density surface
clusters capable of suppressing phagocytosis. In
contrast, apoptotic cells lose CD47 clustering, and
dispersed CD47 becomes unable to protect from
phagocytosis [122]. It is unclear whether senescent
cells reach the stage of CD47 signaling inhibition.
2639Survival networks in senescent cellsNF-κB-dependent pro-inflammatory signaling ap-
pears to directly upregulate CD47, at least in some
cancers, facilitating their escape from immune
surveillance [123]. As NF-κB is considered a master
regulator of the SASP, it is tempting to speculate
senescent cells may continue to display sufficient
levels of CD47. Also, the treatment of endothelial
cells with thrombospondin-1, a CD47 ligand, results
in cell cycle stalling and senescence induction
[124,125]. Recently, Casey et al. [126] described
that the downregulation of CD47 and of the immune
checkpoint inhibitor PD-L1 in cancer cells led to
senescence through the inactivation of Myc onco-
gene. Later evidence revealed that DNA-damaged
cancer cells upregulate the immune checkpoint
inhibitor PD-L1 in response to DNA double-strand
breaks, but PD-L1 levels returns back to normal in
the few surviving cells that have entered senescence
[127]. The authors proposed a transient upregulation
of PD-L1 may therefore prevent an overactivation of
the immune system, but PD-L1 overexpression in
non-transformed primary fibroblasts following DNA
damage was not observed [127]. Put together, these
findings suggest that the senescent program does
not involve the upregulation of immune checkpoint
inhibitors in response to DNA damage but may
instead play a role in their downregulation, thereby
facilitating senescent cells surveillance.
Similarly, treatment of tumor cells with cyclin-
dependent kinases 4/6 (CDK4/6) inhibiting drugs
was shown to induce cell cycle arrest and to activate
the expression of endogenous retroviral elements,
which stimulated the production of type III inter-
ferons, leading to enhanced tumor antigen presen-
tation and enhanced anti-tumor immunity [128].
Therefore, in addition to promote cell cycle progres-
sion, CDK4/6 may also promote the upregulation of
immune checkpoint inhibitors, and their inhibition via
CDKis may enhance their susceptibility to immune
checkpoint blockades and immune surveillance.Implications for Senescence Interventions
Increasing evidence suggests that senescent cells
are primed to apoptosis due to unresolved chronic
stresses, and this might favor the efficacy of known
senolytic drugs. In oncology, two-step therapeutic
strategies aim to first induce cancer cells into
senescence via cytotoxic drugs and then to exploit
the vulnerability of senescent cancer cells to apopto-
sis by using senolytics (reviewed in Ref. [129]).
However, given the deleterious roles of senescent
cells and the negative systemic side effects associat-
ed with chemotherapy, these strategies should be
best approached with caution. Recently, the use of
genetic screens and compound libraries has yielded
aurora kinase inhibitors as powerful inducers of
senescence in cancer cells (independent of p53)[130]. Importantly, senescent cancer cells also ac-
quired vulnerability to the anti-apoptotic Bcl-2 inhibitor
ABT-263 regardless of how senescencewas induced.
Further research is needed to assess the effects of
aurora kinase inhibition in normal cells, as opposed to
chemotherapy, in combination with senolytic drugs.
Redundant mechanisms aid cell death prevention
in both senescent and cancer cells, as observed with
anti-apoptotic Bcl-2 family homologs [38]. Neverthe-
less, as senescent cells may rely more on anti-
apoptotic players compared to normal cells that are
free of intracellular stressors, targeting anti-apoptotic
players may still represent a viable therapeutic
strategy. Moreover, different apoptotic mechanisms
exist across different cell types and senescent
programs, and these differences may be exploited
to allow preferential elimination of a specific subtype
of senescent cells. In this respect, targeting a defined
senescent subtype that is relevant to a specific
pathology may be more desirable and with less side
effects than simultaneously targeting all types of
senescent cells.
It is important to note that senescent cells rely on
multiple levels of regulation in order to achieve
apoptosis resistance. The concurrent targeting of
multiple and indirectly related anti-apoptotic path-
ways (SCAPs) may therefore result in increased
sensitivity of senescent cells without incurring in
toxicities for normal proliferating or quiescent cells. A
combinatorial approach to senescent cell clearance
is exemplified by the concomitant treatment of
dasatinib and quercetin [62]. Targeting SCAP
networks, as opposed to single targets, may enable
lowering the therapeutic dosage of each drug,
therefore decreasing off- and on-target side effects
associated with single drugs. This is also demon-
strated in tumor contexts, where the combination of
metformin, a known inhibitor of the SASP, was able
to decrease the dose of chemotherapy required for
prolonged tumor remission [131]. Combined treat-
ment at lower doses may also allow the repurposing
of known drugs with senolytic potential that were
previously discarded due to undesirable side effects,
therefore improving their chance of success in
clinical trials.
Despite an increased resistance to certain apo-
ptotic stimuli, senescent cells may be more suscep-
tible to various forms of metabolic targeting.
Senescent cell hypercatabolism can be pharmaco-
logically exploited for the elimination of senescent
cells by means of synthetic lethal approaches such
as glycolysis inhibition [82], autophagy inhibition
[82], and mitochondrial targeting [87]. Synthetic
lethal metabolic targeting could therefore be used
alone or in combination with SCAP inhibitors for
increased selectivity.
Finally, additional strategies alternative to apopto-
sis induction may be employed to alleviate the
deleterious phenotypes associated with senescent
2640 Survival networks in senescent cellscells. For instance, the use of SASP modulators may
prevent the establishment of a chronic SASP and
dampen the negative side-effects of senescent cell
persistence without the need for their removal from
tissues. Similarly, the use of selective inhibitors for
specific SASP components, such as neutralizing
antibodies, may allow a tailoring of the SASP by only
targeting SASP components thought to play a
negative role in the tissue micro-environment while
preserving the beneficial ones. Lastly, enhancing the
natural clearance of senescent cells by the immune
system could be another way of overcoming apopto-
sis resistance. The use of immune modulators or
artificially increasing the number of immune effector
cells may effectively restore senescence surveillance
and decrease the senescent cell burden. These
strategies have been recently described to more
detail elsewhere (reviewed in Refs. [132],[133]).Concluding Remarks
Senescent cells possess several adaptations in
order to prevent cell death, and various features of
the senescent phenotype directly contribute to an
increased survival. Major efforts have been spent to
identify and target pathways conferring resistance to
apoptosis. However, most findings on apoptosis
resistance have been reported in human fibroblasts,
and underlying mechanisms are not necessarily
conserved throughout cell types or across the various
senescence programs. An important concept, support-
ed by preliminary evidence, is that senescent cellsmay
have an increased susceptibility to alternative forms of
regulated cell death, but the molecular mechanisms
remain poorly understood. Furthermore, it is unclear
which senescent cell types contribute the most to their
deleterious effects and thus warrant preferential
targeting. Additional research into the mechanisms of
apoptosis resistance in other cell types as well as their
forms of cell death is required in order to identify
exploitable differences for selective targeting.Acknowledgments
We would like to thank members of Quax and
Demaria laboratory for providing feedbacks and
useful discussions. This research was supported
by the University of Groningen (A.S.-G., W.Q., and
M.D.), the Mexican National Council of Science and
Technology (CONACYT) (A.S.-G.), and the Dutch
Cancer Foundation (KWF) (M.D) 10989. Figures
were generated making use of the freeware image
library available at https://www.somersault1824.
com/resources (CC-BY-NC-SA 4.0).Received 2 April 2019;
Received in revised form 20 May 2019;







SAGA, senescence-associated growth arrest; SASP,
senescence-associated secretory phenotype; SCAP, se-
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